The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival

Autor: Theresa J. Hydes, Daniel J. Cuthbertson, Suzanne Graef, Sarah Berhane, Mabel Teng, Anna Skowronska, Pushpa Singh, Sofi Dhanaraj, Abd Tahrani, Philip J. Johnson

Publikováno v: Clinical Therapeutics

The incidence of hepatocellular carcinoma (HCC) in the United Kingdom has increased 60% in the past 10 years. The epidemics of obesity and type 2 diabetes are contributing factors. In this article, we examine the impact of diabetes and glucose-loweri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb904dfe74a71b159c5d02ff12e24b3
http://livrepository.liverpool.ac.uk/3148041/1/ViewPageProof_CLITHE_4149.pdf

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

Autor: Chrysanthia A. Leontiou, Paolo Dalino, Giulia Franchi, Nabila Salahuddin, Antônio Ribeiro de Oliveira, Mabel Teng, Simona Grozinsky-Glasberg, Márta Korbonits, Ashley B. Grossman

Background/Aim: The mode of action of the somatostatin analog octreotide on neuro-endocrine tumour proliferation is largely unknown. Overexpression of the proto-oncogene Akt/PKB (protein kinase B) has been demonstrated in certain neuro-endocrine tumo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73755d363003a15327bd13aebcc2fa5f
https://ora.ox.ac.uk/objects/uuid:2a2e068c-da3c-4b34-8644-c5c97c9af26f

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Autor: Johnson PJ; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan. Philip.Johnson@liverpool.ac.uk., Berhane S; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Kagebayashi C; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Satomura S; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Teng M; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Reeves HL; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., O'Beirne J; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Fox R; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Skowronska A; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Palmer D; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Yeo W; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Mo F; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Lai P; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Iñarrairaegui M; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Chan SL; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Sangro B; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Miksad R; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Tada T; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Kumada T; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan., Toyoda H; Philip J. Johnson, Sarah Berhane, and Daniel Palmer, University of Liverpool, Liverpool; Philip J. Johnson and Daniel Palmer, The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Bebington; Mabel Teng, Addenbrooke's Hospital, University of Cambridge, Cambridge; Helen L. Reeves, Northern Institute for Cancer Research and the Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, The Freeman Hospital, Newcastle upon Tyne; James O'Beirne, The Sheila Sherlock Liver Centre, Royal Free Hospital, London; Richard Fox and Anna Skowronska, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Chiaki Kagebayashi and Shinji Satomura, Wako Life Sciences, Mountain View, CA; Rebecca Miksad, Beth Israel Deaconess Medical Center, Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, MA; Winnie Yeo, Frankie Mo, and Stephen L. Chan, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Chinese University of Hong Kong, Hong Kong Cancer Institute; Paul Lai, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China; Mercedes Iñarrairaegui and Bruno Sangro, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain; Toshifumi Tada, Takashi Kumada, and Hidenori Toyoda, Ogaki Municipal Hospital, Ogaki, Gifu, Japan.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Feb 20; Vol. 33 (6), pp. 550-8. Date of Electronic Publication: 2014 Dec 15.